JP2015524441A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015524441A5 JP2015524441A5 JP2015525575A JP2015525575A JP2015524441A5 JP 2015524441 A5 JP2015524441 A5 JP 2015524441A5 JP 2015525575 A JP2015525575 A JP 2015525575A JP 2015525575 A JP2015525575 A JP 2015525575A JP 2015524441 A5 JP2015524441 A5 JP 2015524441A5
- Authority
- JP
- Japan
- Prior art keywords
- csf
- cancer
- smac
- mimetic
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 38
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 38
- 229940075439 smac mimetic Drugs 0.000 claims description 30
- 210000004027 cell Anatomy 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 230000002062 proliferating effect Effects 0.000 claims description 11
- 230000006907 apoptotic process Effects 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 4
- 230000002159 abnormal effect Effects 0.000 claims description 4
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 claims description 3
- 101710101225 Diablo IAP-binding mitochondrial protein Proteins 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 230000003278 mimic effect Effects 0.000 claims description 3
- 230000001235 sensitizing effect Effects 0.000 claims description 3
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 238000011260 co-administration Methods 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 229940125758 compound 15 Drugs 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
- 238000009169 immunotherapy Methods 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 238000011275 oncology therapy Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000002428 photodynamic therapy Methods 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 15
- 239000003795 chemical substances by application Substances 0.000 claims 11
- 229940079593 drug Drugs 0.000 claims 9
- 230000025915 regulation of apoptotic process Effects 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 16
- 230000005856 abnormality Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261678360P | 2012-08-01 | 2012-08-01 | |
| US61/678,360 | 2012-08-01 | ||
| PCT/US2013/053126 WO2014022612A1 (en) | 2012-08-01 | 2013-08-01 | Combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015524441A JP2015524441A (ja) | 2015-08-24 |
| JP2015524441A5 true JP2015524441A5 (OSRAM) | 2015-11-19 |
Family
ID=50028520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015525575A Pending JP2015524441A (ja) | 2012-08-01 | 2013-08-01 | 併用療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20150190470A1 (OSRAM) |
| EP (1) | EP2879707A4 (OSRAM) |
| JP (1) | JP2015524441A (OSRAM) |
| AU (1) | AU2013296455A1 (OSRAM) |
| CA (1) | CA2880674A1 (OSRAM) |
| HK (1) | HK1210426A1 (OSRAM) |
| NZ (1) | NZ704554A (OSRAM) |
| WO (1) | WO2014022612A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8283372B2 (en) | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
| WO2016097773A1 (en) | 2014-12-19 | 2016-06-23 | Children's Cancer Institute | Therapeutic iap antagonists for treating proliferative disorders |
| EP3558377A1 (en) * | 2016-12-23 | 2019-10-30 | Virttu Biologics Limited | Treatment of cancer |
| WO2023141551A1 (en) * | 2022-01-21 | 2023-07-27 | Partner Therapeutics, Inc. | Granulocyte-macrophage colony-stimulating factor-based dermatological pathology treatments |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100256046A1 (en) * | 2009-04-03 | 2010-10-07 | Tetralogic Pharmaceuticals Corporation | Treatment of proliferative disorders |
| US8202902B2 (en) * | 2006-05-05 | 2012-06-19 | The Regents Of The University Of Michigan | Bivalent SMAC mimetics and the uses thereof |
| EP2049563B1 (en) * | 2006-07-24 | 2014-03-12 | Tetralogic Pharmaceuticals Corporation | Dimeric iap antagonists |
| EP2117579A4 (en) * | 2007-03-07 | 2011-08-24 | Mayo Foundation | TREATMENT OF CANCER USING A GRANULOCYTIC MACROPHAGE COLONY STIMULATING FACTOR |
| JP2010528587A (ja) * | 2007-05-07 | 2010-08-26 | テトラロジック ファーマシューティカルズ コーポレーション | アポトーシス阻害タンパク質のアンタゴニストに対する感受性のバイオマーカーとしてＴＮＦα遺伝子の発現を用いる方法 |
| BRPI0820298A8 (pt) * | 2007-11-09 | 2018-05-08 | Affitech Res As | composições e métodos de anticorpos anti-vegf |
| BRPI0906785A2 (pt) * | 2008-01-24 | 2015-07-14 | Tetralogic Pharm Corp | Composto, composição farmacêutica, e, métodos para induzir a apoptose em uma célula, para tratar câncer e uma doença autoimune |
| WO2010070379A1 (en) * | 2008-12-17 | 2010-06-24 | Centre National De La Recherche Scientifique | Rxr-ppargamma agonist/growth factor inhibitor combination therapy for inducing apoptosis and the treatment of cancer |
| US8283372B2 (en) * | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
| US20140243276A1 (en) * | 2011-09-30 | 2014-08-28 | Tetralogic Pharmaceuticals Corporation | Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer) |
-
2013
- 2013-08-01 JP JP2015525575A patent/JP2015524441A/ja active Pending
- 2013-08-01 EP EP13824904.0A patent/EP2879707A4/en not_active Withdrawn
- 2013-08-01 AU AU2013296455A patent/AU2013296455A1/en not_active Abandoned
- 2013-08-01 NZ NZ704554A patent/NZ704554A/en not_active IP Right Cessation
- 2013-08-01 WO PCT/US2013/053126 patent/WO2014022612A1/en not_active Ceased
- 2013-08-01 HK HK15111260.3A patent/HK1210426A1/xx unknown
- 2013-08-01 CA CA2880674A patent/CA2880674A1/en not_active Abandoned
- 2013-08-01 US US14/418,752 patent/US20150190470A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mrugala | Advances and challenges in the treatment of glioblastoma: a clinician’s perspective | |
| Bae et al. | Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea | |
| Amaram-Davila et al. | Opioids and cancer mortality | |
| Custodio et al. | Targeted therapies for advanced non-small-cell lung cancer: current status and future implications | |
| MY174727A (en) | Stable, protracted glp-1/glucagon receptor co-agonists for medical use | |
| JP2011079858A5 (OSRAM) | ||
| BR112015030377A2 (pt) | preparação compreendendo pelo menos um quimioterápico ou substância citotóxica para uso no tratamento de uma doença de um paciente mamífero, preparação e método para tratamento de câncer em um paciente mamífero através de terapia de radiação | |
| JP2016536352A5 (OSRAM) | ||
| JP2014533272A5 (OSRAM) | ||
| JP2015524441A5 (OSRAM) | ||
| JP2016526531A5 (OSRAM) | ||
| Gou et al. | Induction chronomodulated chemotherapy plus radiotherapy for nasopharyngeal carcinoma: a phase II prospective randomized study | |
| Mazor et al. | Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant Erdheim–Chester disease patients following BRAF inhibitor monotherapy | |
| PH12015502266A1 (en) | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers | |
| JP2014129405A5 (OSRAM) | ||
| Komatsu et al. | Concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with nasopharyngeal carcinoma | |
| Wright et al. | The utility of ketamine for the preoperative management of a patient with Parkinson’s disease | |
| Verma et al. | CHRONOMODULATED CHEMOTHERAPY AND CONCOMITANT RADIOTHERAPY, FOR THE MANAGEMENT OF LOCALLY ADVANCED, HEAD AND NECK SQUAMOUS CELL CARCINOMA. | |
| Liu et al. | Harnessing interventions during the immediate perioperative period to improve the long-term survival of patients following radical gastrectomy | |
| JP2020536068A5 (OSRAM) | ||
| RU2013149175A (ru) | Лекарственное средство, содержащее лектины омелы, для лечения злокачественной меланомы | |
| Schneider et al. | Neutrophil-guided drug delivery for targeting residual glioma cells | |
| McGranahan et al. | Neurologic complications in adult cancer survivorship | |
| Schneider et al. | Missing naïve T cells in the setting of glioblastoma are found to be sequestered in the bone marrow | |
| Trignani et al. | The case of a patient affected by primary gliosarcoma and neuroendocrine pancreatic cancer with prolonged survival |